Previous Close | 0.1895 |
Open | 0.1895 |
Bid | 0.0000 x 0 |
Ask | 0.2000 x 100 |
Day's Range | 0.1826 - 0.2034 |
52 Week Range | 0.1800 - 242.4000 |
Volume | |
Avg. Volume | 2,005,188 |
Market Cap | 1.388M |
Beta (5Y Monthly) | 1.86 |
PE Ratio (TTM) | 0.01 |
EPS (TTM) | 21.9400 |
Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NEW YORK (AP) — Seelos Therapeutics, Inc. SEEL) on Wednesday reported earnings of $1.7 million in its second quarter. The New York-based company said it had profit of 12 cents per share.
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn’t a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy). Likewise, Congressman Da
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares of common stock at a price of $2.46 per share